alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL OF FLORIDA SECOND DISTRICT GEORGE CYLE WILLIAMSON, JR., ) ) Appellant, ) ) v. ) Case No. 2D18-4316 ) STATE OF FLORIDA, ) ) Appellee. ) ___________________________________) Opinion filed September 11, 2019. Appeal pursuant to Fla. R. App. P. 9.141(b)(2) from the Circuit Court for Manatee County; Edward Nicholas, Judge. George Cyle Williamson, Jr., pro se.

PER CURIAM.

Affirmed. NORTHCUTT, BLACK, and BADALAMENTI, JJ., Concur.
# C_2015081EN.01003001.xml

| 9.3.2015 | EN | Official Journal of the European Union | C 81/30 |
| --- | --- | --- | --- |

9.3.2015

EN

Official Journal of the European Union

C 81/30

---

Action brought on 24 December 2014 — ZZ v Eurojust

(Case F-142/14)

(2015/C 081/38)

Language of the case: English

Parties

Parties

Applicant: ZZ (represented by: Ekkehard H. Schulze, Rechtsanwalt)

Applicant:

Defendant: Eurojust

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision not to admit the applicant to the second phase of the selection procedure, in the context of his candidature for the post of Advisor to the Office of the President of Eurojust.

Form of order sought

Form of order sought

| — | annul the decisions of 8 August 2014 and 25 September 2014; |
| --- | --- |

—

annul the decisions of 8 August 2014 and 25 September 2014;

| — | order the defendant to admit the applicant to participate further in the selection process; and |
| --- | --- |

—

order the defendant to admit the applicant to participate further in the selection process; and

| — | order the defendant to pay the costs incurred by the applicant. |
| --- | --- |

—

order the defendant to pay the costs incurred by the applicant.

---
§ 582.1095 Sulfuric acid. ( a ) *Product.* Sulfuric acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 640.80 Albumin (Human). ( a ) *Proper name and definition.* The proper name of the product shall be Albumin (Human). The product is defined as a sterile solution of the albumin derived from human plasma.
( b ) *Source material.* The source material of Albumin (Human) shall be plasma recovered from Whole Blood prepared as prescribed in §§ 640.1 through 640.5, or Source Plasma prepared as prescribed in §§ 640.60 through 640.76.
( c ) *Additives in source material.* Source material shall not contain an additive unless it is shown that the processing method yields a final product free of the additive to such extent that the continued safety, purity, potency, and effectiveness of the final product will not be adversely affected.
[42 FR 27582, May 31, 1977, as amended at 50 FR 4140, Jan. 29, 1985; 64 FR 26286, May 14, 1999]
Exhibit 31.2

CHIEF FINANCIAL OFFICERS

CERTIFICATION UNDER

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Charles A. Rowland, Jr., Chief Financial Officer of the registrant, certify that:



| | 1. | I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of ViroPharma Incorporated; and
| | -- | ----------------------------------------------------------------------------------------------------



| | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                           
|---------------------------
|/s/ CHARLES A. ROWLAND, JR.
|Charles A. Rowland, Jr.    
|Chief Financial Officer    

August 2, 2012
================================================================================

[PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.]

                                  APPENDIX A-5

                                    PRODUCTS


Product Name:     HOT DOG EXPRESS, Part # RG-99

Product Description: Kitchen Appliance that mainly cooks Hot Dogs

Projected Units Sold next 24 months: XXXXXX

Manufacturer:     CirTran-Asia

Sub-Manufacturer: Jion Loen Enterprise Co., Ltd.
                  Civil Industries Ltd.
                  Zhejiang Hengtai Machinery Manufacturing Co., Ltd.

Marketing Partner Contact Info:     EMSON PRODUCTS, INC.

Current Sale Price: $XXXXXX USD - CIRTRAN-ASIA

Current Cost to Manufacturer:       $ XXXXXX USD

Total Tooling/Development Costs:    $100,000 USD

Gross Profit Margin Per Unit - $2.50

CirTran-Asia               $ 0.65 USD
Charles Ho                 $ 1.85 USD

Hot Dog Express Stock Option Schedule

Upon full execution of this Agreement, Cirtran's parent CirTran Corporation will
issue the following options to purchase restricted common stock:

                   Charles Ho                700,000 shares
                   Michael Casey             300,000 shares

These initial options will vest and be exercisable only after Cirtran has sold
300,000 HOT DOG EXPRESS units. The options will be exercisable at $.06 per share
after vesting. The options will expire and will no longer be exercisable on the
date one year after the date hereof.

In addition, for each whole multiple of 100,000 HOT DOG units sold by Cirtran
during the first 24 months of this Agreement in excess of the initial 300,000
units, CirTran Corporation will grant each Charles Ho and Michael Casey an
option to purchase 100,000 shares. Each such additional option will be
exercisable for a period of 12 months at an exercise price equal to the fair
market value of CirTran Corporation stock on the date of grant (i.e. the mean
between the high bid and low asked prices for the stock for the date of
determination).

As a condition to grant of the options, each option holder will be required to
make standard investment representations to CirTran Corporation.

[XXXXX - REDACTED PURSUANT TO REQUEST FOR CONFIDENTIAL TREATMENT FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.]


--------------------------------------------------------------------------------
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Small Business Administration [Disaster Declaration # 12038 and # 12039]
 AGENCY: U.S. Small Business Administration.
 ACTION: Notice.
 SUMMARY: This is a notice of an Administrative declaration of a disaster for the State of California dated 02/16/2010. *Incident:*
                         Severe Winter Storms, Heavy Snow, Flooding, Debris Flows and Mudslides. *Incident Period:*
                         01/17/2010 and continuing.
 DATES: *Effective Date:*
                         02/16/2010. *Physical Loan Application Deadline Date:*
                         04/19/2010. *Economic Injury (Eidl) Loan Application Deadline Date:*
                         11/16/2010.
 ADDRESSES: Submit completed loan applications to: U.S. Small Business  Administration, Processing and Disbursement Center, 14925 Kingsport Road, Fort Worth, TX 76155.
 FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster Assistance, U.S. Small Business Administration, 409 3rd Street, SW., Suite 6050, Washington, DC 20416.


SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of the Administrator's disaster declaration, applications for disaster loans may be filed at the address listed above or other locally announced locations. The following areas have been determined to be adversely affected by the disaster: *Primary Counties:*
                     Los Angeles. *Contiguous Counties:* California: Kern, Orange San Bernardino, Ventura. The Interest Rates are: Percent*For Physical Damage:*Homeowners With Credit Available Elsewhere
5.125Homeowners Without Credit Available Elsewhere
2.562Businesses With Credit Available Elsewhere
6.000Businesses Without Credit Available Elsewhere
4.000Non-Profit Organizations With Credit Available Elsewhere
3.625Non-Profit Organizations Without Credit Available Elsewhere
3.000*For Economic Injury:*Businesses & Small Agricultural Cooperatives Without Credit Available Elsewhere
4.000Non-Profit Organizations Without Credit Available Elsewhere
3.000
 The number assigned to this disaster for physical damage is 12038 B and for economic injury is 12039 0. The States which received an EIDL Declaration # are California. (Catalog of Federal Domestic Assistance Numbers 59002 and 59008) Dated: February 16, 2010. Karen G. Mills, Administrator.


[FR Doc. 2010-3614 Filed 2-23-10; 8:45 am] BILLING CODE 8025-01-P
May 23, 1996




Hans Olsen
NewLogic
11805 NE 99th Street, Suite 1320
Vancouver, WA 98682

Dear Hans:

         I am very  pleased to offer you the  position of Vice  President of the
Systems Group,  reporting to me. The annual salary for this position is $150,000
payable (in increments) every two weeks. As an employee of the Company, you will
be entitled to receive such other benefits customarily afforded employees of the
Company.

         You will be granted a stock option to purchase  50,000  shares of stock
at an exercise  price  which will be the closing  price of our stock the day the
acquisition of NewLogic by Paradigm is completed.  Your stock will begin to vest
two years after the acquisition is completed and will vest 25% per year for four
years.

         You should be aware  that your  employment  with the  Company is freely
entered into and is for no specified  period of time. As a result,  you are free
to resign at any time, for any reason or for no reason.  Similarly,  the Company
is free to conclude its employment  relationship  with you at any time,  with or
without cause.

         For  purposes  of Federal  Immigration  Law,  you will be  required  to
provide to the Company documentary evidence of your identity and eligibility for
employment  in the United  States.  Such  documentation  must be  provided to us
within three business days of your date of hire.

         In the event of any  dispute or claim  related to or arising out of our
employment relationship,  you and the Company agree that all such disputes shall
be fully and finally resolved by binding  arbitration  conducted by the American
Arbitration  Association in San Jose,  California.  However,  we agree that this
arbitration  provision  shall not apply to any disputes or claims relating to or
arising out of the misuse or  misappropriation of the Company's trade secrets or
proprietary information.

         To indicate your  acceptance of the  Company's  offer,  please sign and
date this  letter in the space  provided  below and return it to me.  Your start
date will be the day the acquisition of NewLogic by Paradigm is completed.




<PAGE>


         This letter,  along with any agreements  relating to proprietary rights
between you and the Company, and the agreements  associated with the acquisition
of NewLogic by Paradigm set forth the terms of your  employment with the Company
and supersede any prior representations or agreements,  whether written or oral.
This letter may not be modified or amended except by written  agreement,  signed
by you and the Company.

         We look  forward to working  with you at Paradigm  Technology.  Welcome
aboard!

                                     Sincerely,




                                     Michael Gulett
                                     President and CEO



The undersigned  hereby accepts the position at Paradigm and agrees to the terms
of employment as set forth above.



-----------------------------------
Hans Olsen


-----------------------------------
Date
EXHIBIT 32.2

CERTIFICATION

I, Gregory A. Wells, Chief Financial
Officer of NTS Capital Corporation, the general partner of NTS- Properties Associates VII, the
general partner of NTS-Properties VII, Ltd. (the Partnership), certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

|1. |  | The quarterly report on Form 10-Q of the Partnership for the period ended March
               31, 2004 (the Report) fully complies with the requirements of
               Section 13(a) of the Securities Exchange Act of 1934, as amended; and
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|2. |  | The information contained in the Report fairly presents, in all material
               respects, the financial condition and results of operations of the Partnership.
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dated: May 13, 2004

/s/ Gregory A. Wells

---

Chief Financial Officer of NTS Capital Corporation,
General Partner of NTS-Properties Associates VII,
General Partner of NTS-Properties VII, Ltd.

A signed original of this written
statement required by Section 906 has been provided to the Partnership and will be
retained by the Partnership and furnished to the Securities and Exchange Commission or its
staff upon request.
[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Pages 9454-9455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4333]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION


Sunshine Act Meeting

    Notice is hereby given, pursuant to the provisions of the 
Government in the Sunshine Act, Public Law 94-409, that the Securities 
and Exchange Commission will hold a Closed Meeting on Thursday, March 
4, 2010 at 2 p.m.
    Commissioners, Counsel to the Commissioners, the Secretary to the 
Commission, and recording secretaries will attend the Closed Meeting. 
Certain staff members who have an interest in the matters also may be 
present.
    The General Counsel of the Commission, or his designee, has 
certified that, in his opinion, one or more of the exemptions set forth 
in 5 U.S.C. 552b(c)(3), (5), (7), 9(B) and (10) and 17 CFR 
200.402(a)(3), (5), (7), 9(ii) and (10), permit consideration of the 
scheduled matters at the Closed Meeting.
    Commissioner Aguilar, as duty officer, voted to consider the items 
listed for the Closed Meeting in a closed session.
    The subject matter of the Closed Meeting scheduled for Thursday, 
March 4, 2010 will be:
    Institution and settlement of injunctive actions; institution and 
settlement of administrative proceedings; and other matters relating to 
enforcement proceedings.
    At times, changes in Commission priorities require alterations in 
the scheduling of meeting items.
    For further information and to ascertain what, if any, matters have 
been

[[Page 9455]]

added, deleted or postponed, please contact:
    The Office of the Secretary at (202) 551-5400.

    Dated: February 25, 2010.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2010-4333 Filed 2-26-10; 11:15 am]
BILLING CODE 8011-01-P
§ 520.2043 Pyrantel pamoate suspension. ( a ) *Specifications.* ( 1 ) Each milliliter (mL) contains pyrantel pamoate equivalent to 50 milligrams (mg) pyrantel base.
( 2 ) Each mL contains pyrantel pamoate equivalent to 2.27 or 4.54 mg pyrantel base.
( 3 ) Each mL contains pyrantel pamoate equivalent to 4.54 mg pyrantel base.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for uses as in paragraph (d) of this section. ( 1 ) Nos. 054771, 058829, and 069043 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section.
( 2 ) Nos. 054771, 058198, and 058829 for use of the products described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
( 3 ) No. 023851 for use of the product described in paragraph (a)(3) as in paragraph (d)(2) of this section.
( c ) *Special considerations.* See § 500.25 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Horses and ponies.* It is used as follows: ( i ) *Amount.* 3 mg per pound (/lb) body weight as a single dose mixed with the usual grain ration, or by stomach tube or dose syringe.
( ii ) *Indications for use.* For the removal and control of mature infections of large strongyles (*Strongylus vulgaris, S. edentatus, S. equinus*); pinworms (*Oxyuris equi*); large roundworms (*Parascaris equorum*); and small strongyles.
( iii ) *Limitations.* Do not use in horses intended for human consumption. When the drug is for administration by stomach tube, it shall be labeled: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”
( 2 ) *Dogs.* It is used as follows: ( i ) *Dogs and puppies* — ( A ) *Amount.* 2.27 mg/lb body weight as a single dose in the animal's feed bowl by itself or mixed in a small quantity of food.
( B ) *Indications for use.* For the removal of large roundworms (*Toxocara canis* and *Toxascaris leonina*) and hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*).
( C ) *Limitations.* Additional treatment may be required and should be confirmed by fecal examination within 2 to 4 weeks.
( ii ) *Dogs, puppies, and lactating bitches after whelping* — ( A ) *Amount.* 2.27 mg/lb body weight.
( B ) *Indications for use.* To prevent reinfections of *T. canis.*
( C ) *Limitations.* Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals.
[67 FR 43248, June 27, 2002, as amended at 68 FR 54803, Sept. 19, 2003; 68 FR 55199, Sept. 23, 2003; 68 FR 55825, Sept. 29, 2003; 75 FR 52622, Aug. 27, 2010; 76 FR 17337, Mar. 29, 2011; 78 FR 17596, Mar. 22, 2013; 79 FR 28827, May 20, 2014; 80 FR 76386, Dec. 9, 2015; 81 FR 17607, Mar. 30, 2016; 86 FR 14819, Mar. 19, 2021]
* Pursuant to Local Rule 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in Local Rule 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 96-20656

 

BOB STRAUS,

Plaintiff-Appellee,

versus

RON ANGLE,

Defendant-Appellant.

 

Appeal from the United States District Court

For the Southern District of Texas 

 

April 22, 1997

Before REYNALDO G. GARZA, HIGGINBOTHAM, and JONES, Circuit Judges.

PER CURIAM:*

We are persuaded that the district court lacked personal

jurisdiction. The judgment below is reversed. The case is

remanded with instructions to the district court to dismiss for

want of jurisdiction.
<TABLE> <S> <C>

<ARTICLE>                                   5
<LEGEND>
     This schedule  contains summary  financial  information  extracted from the
Partnership's unaudited financial statements for the quarter ended June 30, 1998
and is qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                            1,000
       
<S>                                       <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                  MAR-31-1999
<PERIOD-END>                       JUN-30-1998
<CASH>                                  6,031
<SECURITIES>                                0
<RECEIVABLES>                              61
<ALLOWANCES>                                0
<INVENTORY>                                 0
<CURRENT-ASSETS>                        6,145
<PP&E>                                 23,042
<DEPRECIATION>                          4,181
<TOTAL-ASSETS>                         25,110
<CURRENT-LIABILITIES>                  10,640
<BONDS>                                 3,481
<PREFERRED-MANDATORY>                       0
<PREFERRED>                                 0
<COMMON>                                    0
<OTHER-SE>                             10,989
<TOTAL-LIABILITY-AND-EQUITY>           25,110
<SALES>                                     0
<TOTAL-REVENUES>                          677
<CGS>                                       0
<TOTAL-COSTS>                             324
<OTHER-EXPENSES>                            0
<LOSS-PROVISION>                            0
<INTEREST-EXPENSE>                        449
<INCOME-PRETAX>                          (96)
<INCOME-TAX>                                0
<INCOME-CONTINUING>                      (96)
<DISCONTINUED>                              0
<EXTRAORDINARY>                             0
<CHANGES>                                   0
<NET-INCOME>                             (96)
<EPS-PRIMARY>                          (1.88)
<EPS-DILUTED>                          (1.88)
        

</TABLE>
# C_2019385EN.01000101.xml

| 13.11.2019 | EN | Official Journal of the European Union | C 385/1 |
| --- | --- | --- | --- |

13.11.2019

EN

Official Journal of the European Union

C 385/1

---

COUNCIL RECOMMENDATION

of 8 November 2019

on the appointment of a member of the Executive Board of the European Central Bank

(2019/C 385/01)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Articles 283(2) and 139(2) thereof,

Having regard to Protocol No 4 on the Statute of the European System of Central Banks and of the European Central Bank, and in particular Article 11.2 thereof,

HEREBY RECOMMENDS TO THE EUROPEAN COUNCIL THAT:

Ms Isabel SCHNABEL be appointed as a member of the Executive Board of the European Central Bank for a term of office of eight years with effect from 1 January 2020.

Done at Brussels, 8 November 2019.

For the Council

The President

M. LINTILÄ

---